Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy

Table 3 Comparison of the CU-hepatocellular carcinoma, GAG-hepatocellular carcinoma and REACH-B scores

Score	Patients	Components	Cutoff value	Performance
CU-HCC	Clinic patients: 1005 in training cohort, 424 in validation cohort	Age, albumin, bilirubin, HBV DNA, cirrhosis	5	97% NPV at 10 yr
GAG-HCC	820 clinic patients (leave-one-out cross-validation method)	Age, gender, HBV DNA, cirrhosis	101	99% NPV at 10 yr
REACH-B	Non-cirrhotic patients: 3584 in training cohort, 1505 in validation cohort	Age, gender, ALT, HBV DNA, HBeAg	8	98% NPV at 10 yr

ALT: Alanine aminotransferase; HBeAg: Hepatitis B e antigen; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; NPV: Negative predictive value.